Cefepime-Resistant Pseudomonas aeruginosa

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Akhabue, Ehimare ; Synnestvedt, Marie ; Weiner, Mark G. ; Bilker, Warren B. ; Lautenbach, Ebbing
• Description:
  Resistance to extended-spectrum cephalosporins complicates treatment of Pseudomonas aeruginosa infections. To elucidate risk factors for cefepime-resistant P. aeruginosa and determine its association with patient death, we conducted a case-control study in Philadelphia, Pennsylvania. Among 2,529 patients hospitalized during 2001-2006, a total of 213 (8.4%) had cefepime-resistant P. aeruginosa infection. Independent risk factors were prior use of an extended-spectrum cephalosphorin (p<0.001), prior use of an extended-spectrum penicillin (p = 0.005), prior use of a quinolone (p<0.001), and transfer from an outside facility (p = 0.01). Among those hospitalized at least 30 days, mortality rates were higher for those with cefepime-resistant than with cefepime-susceptible P. aeruginosa infection (20.2% vs. 13.2%, p = 0.007). Cefepime-resistant P. aeruginosa was an independent risk factor for death only for patients for whom it could be isolated from blood (p = 0.001). Strategies to counter its emergence should focus on optimizing use of antipseudomonal drugs.
• Subjects:
  Anti-Bacterial Agents Bacteria Case-Control Studies Cefepime Cephalosporins Cme Drug Resistance, Bacterial Female Humans Male Microbial Sensitivity Tests Middle Aged Outcomes Pseudomonas Aeruginosa Pseudomonas Infections Research Resistance Risk Factors

  More +
• Source:
  Emerg Infect Dis. 17(6):1037-1043.
• Document Type:
  Journal Article
• Volume:
  17
• Issue:
  6
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:f5036a3b2e62ce81741cf61bce38166701b07bfaff66da40c3f91a5fc288e3b8
• Download URL:
  https://stacks.cdc.gov/view/cdc/18279/cdc_18279_DS1.pdf
• File Type:
  [PDF - 155.25 KB ]